دورية أكاديمية
Recent advances in understanding cholangiocarcinoma.
| العنوان: | Recent advances in understanding cholangiocarcinoma. |
|---|---|
| المؤلفون: | Uson Junior PLS; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.; Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Arora M; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA., Bogenberger JM; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA., Borad MJ; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona, USA. |
| المصدر: | Faculty reviews [Fac Rev] 2020 Nov 19; Vol. 9, pp. 15. Date of Electronic Publication: 2020 Nov 19 (Print Publication: 2020). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Faculty Opinions Country of Publication: England NLM ID: 101769226 Publication Model: eCollection Cited Medium: Internet ISSN: 2732-432X (Electronic) Linking ISSN: 2732432X NLM ISO Abbreviation: Fac Rev Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: London : Faculty Opinions Original Publication: London : F1000 Research, [2020]- |
| مستخلص: | The definition of cholangiocarcinoma (CCA) encompasses all tumors originating in the epithelium of the bile ducts, including the intrahepatic bile ducts (ICCA) and extrahepatic bile ducts (ECCA). The incidence of ICCA and ECCA has increased in the last few decades, and molecular advances in both entities have brought understanding of their differences and allowed treatment advances aimed at personalized therapy. In this review, we discuss recent progress in the molecular landscape of CCAs, emerging treatment biomarker-guided strategies, and future insights into the management of advanced disease. Competing Interests: The authors declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed. (Copyright: © 2020 Borad MJ et al.) |
| References: | J Gastrointest Oncol. 2019 Dec;10(6):1099-1109. (PMID: 31949927) J Clin Oncol. 2018 Jan 20;36(3):276-282. (PMID: 29182496) Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. (PMID: 32606456) Lancet Oncol. 2019 May;20(5):663-673. (PMID: 30922733) Chin Clin Oncol. 2016 Oct;5(5):62. (PMID: 27829276) CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402) Lancet Oncol. 2020 May;21(5):671-684. (PMID: 32203698) Transplantation. 2006 Dec 27;82(12):1703-7. (PMID: 17198263) Transplantation. 2020 Oct;104(10):2097-2104. (PMID: 31972704) N Engl J Med. 2017 Oct 12;377(15):1409-1412. (PMID: 29020592) Cancer Discov. 2019 Aug;9(8):1064-1079. (PMID: 31109923) Cancer. 2002 Oct 15;95(8):1685-95. (PMID: 12365016) Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720. (PMID: 31300360) Nat Genet. 2015 Sep;47(9):1003-10. (PMID: 26258846) J Clin Oncol. 2015 Aug 20;33(24):2617-22. (PMID: 25964250) Lancet Oncol. 2020 Jun;21(6):796-807. (PMID: 32416072) Oncologist. 2012;17(1):72-9. (PMID: 22180306) Liver Transpl. 2007 Oct;13(10):1372-81. (PMID: 17427173) Br J Surg. 2018 Feb;105(3):192-202. (PMID: 29405274) Clin Cancer Res. 2019 May 1;25(9):2699-2707. (PMID: 30745300) BMC Cancer. 2019 Jan 15;19(1):72. (PMID: 30646854) N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255) Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14. (PMID: 22504095) Ann Surg. 2018 May;267(5):797-805. (PMID: 29064885) JAMA Oncol. 2020 Jun 1;6(6):888-894. (PMID: 32352498) JAMA Surg. 2015 Jun;150(6):538-45. (PMID: 25831462) NPJ Precis Oncol. 2018 Oct 3;2:21. (PMID: 30302397) Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4):. (PMID: 31371345) Cancer Discov. 2017 Mar;7(3):252-263. (PMID: 28034880) J Clin Oncol. 2019 Mar 10;37(8):658-667. (PMID: 30707660) Br J Cancer. 2019 Jan;120(2):165-171. (PMID: 30420614) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) N Engl J Med. 2010 Apr 8;362(14):1273-81. (PMID: 20375404) Oncologist. 2015 Sep;20(9):1019-27. (PMID: 26245674) |
| فهرسة مساهمة: | Keywords: Cholangiocarcinoma; FGFR2; IDH1; PD-1; biliary tract cancer |
| تواريخ الأحداث: | Date Created: 20210304 Latest Revision: 20210305 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7886064 |
| DOI: | 10.12703/b/9-15 |
| PMID: | 33659947 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2732-432X |
|---|---|
| DOI: | 10.12703/b/9-15 |